Biblio Discovery — Demo Discovery Service

22 hasil untuk "Torben Plesner"

Menampilkan 1–20 · 0,44 detik · RSS

  1. Artikel Jurnal

    Daratumumab for the Treatment of Multiple Myeloma

    Torben Plesner; Jakub Krejcik

    Frontiers in Immunology, Vol. 9 · 2018 · Inggris · DOAJ Scopus

    This mini-review will summarize the present state of development of the CD38 antibody daratumumab for the treatment of multiple myeloma.

  2. Artikel Jurnal

    High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4+ T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens

    Katrine Fladeland Iversen; Line Nederby; Thomas Lund dkk.

    Clinical Hematology International, Vol. 4 No. 3 · 2022 · Inggris · DOAJ Scopus

    Abstract Multiple myeloma is an incurable disease characterized by unregulated growth of malignant plasma cells in the bone marrow (BM). Tumor-induced dysfunction of T-cells may be responsible for immune evasion and failure of immunotherapy. Therefore, a better understanding of the phenotype of…

  3. Artikel Jurnal

    The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study

    Agoston Gyula Szabo; Katrine Fladeland Iversen; Sören Möller dkk.

    Clinical Hematology International, Vol. 1 No. 4 · 2019 · Inggris · DOAJ Scopus

    In this retrospective study we reviewed the clinical course of every patient with multiple myeloma treated from 2006 to 2016 at Vejle Hospital: 303 patients with a median age of 69 years at diagnosis received a median of four (range 1–18) lines of therapy; 149 in a 2006–2010 cohort and 154 in a…

  4. Artikel Jurnal Teks lengkap

    Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?

    Torben Plesner; Niels W. C. J. van de Donk; Paul G. Richardson

    Cells, Vol. 9 No. 2 · 2020 · Inggris · DOAJ Scopus

    During a time span of just a few years, the CD38 antibody, daratumumab, has been established as one of the most important new drugs for the treatment of multiple myeloma, both in the relapsed/refractory setting and, more recently, as a first-line treatment. Although much is known about the…

  5. Artikel Jurnal Teks lengkap

    Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59

    Kieran Brennan; Katrine F. Iversen; Alfonso Blanco-Fernández dkk.

    Cells, Vol. 11 No. 21 · 2022 · Inggris · DOAJ Scopus

    Daratumumab (DARA) has improved the outcome of treatment of multiple myeloma (MM). DARA acts via complement-dependent and -independent mechanisms. Resistance to DARA may result from upregulation of the complement inhibitory proteins CD55 and CD59, downregulation of the DARA target CD38 on myeloma…

  6. Artikel Jurnal

    Identification of Extracellular Vesicle Signatures of Daratumumab Treated Multiple Myeloma

    Kieran Brennan; Katrine F. Iversen; Alfonso Blanco‐Fernández dkk.

    Journal of Extracellular Vesicles, Vol. 15 No. 2 · 2026 · Inggris · DOAJ Scopus

    ABSTRACT Daratumumab (DARA) is a human monoclonal antibody for the treatment of multiple myeloma (MM), an incurable hematologic malignancy characterised by the accumulation of malignant plasma cells, located in the bone marrow (BM). We previously reported that peripheral blood plasma (PB)…

  7. Bab Buku Teks lengkap

    Bone Disease in Multiple Myeloma

    Maja Hinge; Thomas Lund; Jean-Marie Delaisse dkk.

    Multiple Myeloma - A Quick Reflection on the Fast Progress · 2013 · Inggris · IntechOpen

  8. Artikel Jurnal

    Up-front fludarabine impairs stem cell harvest in multiple myeloma: report from an interim analysis of the NMSG 13/03 randomized placebo controlled phase II trial

    Hans E. Johnsen; Lene M. Knudsen; Anne K. Mylin dkk.

    Hematology Reports, Vol. 1 No. 2 · 2009 · Inggris · DOAJ Scopus

    The impact of chemotherapy resistant B cells in multiple myeloma (MM) needs to be evaluated by in vivo targeted therapy. Here we report the conclusions from a phase II randomized, placebo controlled trial adding fludarabine to the induction with cyclophosphamide-dexamethasone. Based on an interim…

  9. Artikel Jurnal

    Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

    Tineke Casneuf; Xu Steven Xu; Homer C. Adams, III dkk.

    Blood Advances, Vol. 1 No. 23 · 2017 · Inggris · DOAJ Scopus

    Abstract: Daratumumab, a human CD38 imunoglobulin G 1κ monoclonal antibody, has demonstrated clinical activity and a manageable safety profile in monotherapy and combination therapy clinical trials in relapsed and/or refractory multiple myeloma. CD38 is expressed at high levels on myeloma cells…

  10. Artikel Jurnal

    Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma

    Torben Plesner; Simon J. Harrison; Hang Quach dkk.

    Clinical Hematology International, Vol. 5 No. 1 · 2023 · Inggris · DOAJ Scopus

    Abstract Introduction This phase 1 trial assessed the safety, pharmacokinetics, and preliminary antitumor activity of RO7297089, an anti-BCMA/CD16a bispecific antibody. Methods RO7297089 was administered weekly by intravenous infusion to patients with relapsed/refractory multiple myeloma. The…

  11. Artikel Jurnal

    The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network

    Niels W.C.J. van de Donk; Antonio Palumbo; Hans Erik Johnsen dkk.

    Haematologica, Vol. 99 No. 6 · 2014 · Inggris · DOAJ Scopus

    Monoclonal gammopathy of undetermined significance is one of the most common pre-malignant disorders. IgG and IgA monoclonal gammopathy of undetermined significance are precursor conditions of multiple myeloma; light-chain monoclonal gammopathy of undetermined significance of light-chain multiple…

  12. Artikel Jurnal

    Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)

    Jesus San-Miguel; Saad Z. Usmani; Maria-Victoria Mateos dkk.

    Haematologica, Vol. 106 No. 6 · 2020 · Inggris · DOAJ Scopus

    Intravenous daratumumab is approved for the treatment of multiple myeloma. In Part 1 of the PAVO study, a mix-and-deliver subcutaneous formulation of daratumumab with recombinant human hyaluronidase PH20 (rHuPH20) was well tolerated, with low rates of infusion-related reactions and similar efficacy…